Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 11/26 11:30:00 am
7785 GBX   -0.19%
05:16pNEWS HIGHLIGHTS : Top Company News of the Day
DJ
03:31pASTRAZENECA : says working with regulators on best approach to lower dose regimen
RE
03:16pNEWS HIGHLIGHTS : Top Company News of the Day
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bharat Biotech in talks to take vaccine candidate global

10/23/2020 | 10:22am EST
FILE PHOTO: Small bottles labeled with

BENGALURU (Reuters) - India's Bharat Biotech is in discussions with more than 10 countries that have shown an interest in a potential COVID-19 vaccine it is developing with a government agency, a company executive told Reuters on Friday.

The company, based in Hyderabad, this week received initial approval from Indian authorities to conduct late-stage trials for its vaccine candidate, COVAXIN.

The potential vaccine was found to be safe without any major adverse events in the first two stages of the trials involving about 1,000 people, Executive Director Sai Prasad said in a phone interview, adding that more than 90% of them developed antibodies against the novel coronavirus.

The focus now was on last-stage trials of the vaccine, developed in collaboration with the Indian Council of Medical Research, as well as seeking foreign partners, he said.

"We are in active discussions with more than 10 countries that have shown an interest in COVAXIN," he said.

"We are talking to some of the countries about partnerships to conduct clinical trials and introduce the vaccine, and in some countries we are in talks to manufacture the vaccine locally."

He declined to name the countries but said they were located in South America, Asia and central Asia, and Eastern Europe.

For third-stage trials in India, Bharat Biotech plans to enrol about 25,000 to 26,000 participants in around 12-14 states, he added.

India's Zydus Cadila is currently conducting mid-stage trials of its own vaccine hopeful, while Serum Institute is making potential vaccines from AstraZeneca, Novavax and Codagenix Inc, as well as developing its own.

India has the world's second-highest number of reported coronavirus cases at 7.8 million, more than a 100,000 of whom have died.

($1 = 73.7434 rupees)

(Reporting by Anuron Kumar Mitra in Bengaluru; Writing by Shilpa Jamkhandikar; Editing by Alex Richardson)

By Anuron Kumar Mitra


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.67% 7748 Delayed Quote.1.85%
CADILA HEALTHCARE LIMITED 0.19% 422.3 Delayed Quote.65.75%
NOVAVAX, INC. 7.63% 102.6 Delayed Quote.2,477.89%
All news about ASTRAZENECA PLC
05:16pNEWS HIGHLIGHTS : Top Company News of the Day
DJ
03:31pASTRAZENECA : says working with regulators on best approach to lower dose regime..
RE
03:16pNEWS HIGHLIGHTS : Top Company News of the Day
DJ
02:11pRussia's Sputnik V developers call on AstraZeneca to try combining vaccines
RE
01:16pNEWS HIGHLIGHTS : Top Company News of the Day
DJ
12:51pASTRAZENECA : Top UK scientific adviser says AstraZeneca vaccine works
RE
11:54aAstraZeneca CEO expects to run new global trial of COVID-19 vaccine - Bloombe..
RE
11:16aNEWS HIGHLIGHTS : Top Company News of the Day
DJ
10:58aANALYSIS : Questions over AstraZeneca's COVID-19 vaccine data risk delaying appr..
RE
10:06aWhy the Oxford Astrazeneca Vaccine Is Now a Global Gamechanger
AQ
More news
Financials (USD)
Sales 2020 26 512 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 46,6x
Yield 2020 2,72%
Capitalization 136 B 136 B -
EV / Sales 2020 5,62x
EV / Sales 2021 4,89x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121,48 $
Last Close Price 103,46 $
Spread / Highest target 50,3%
Spread / Average Target 17,4%
Spread / Lowest Target -36,2%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC1.85%137 013
JOHNSON & JOHNSON-1.50%378 244
ROCHE HOLDING AG-4.41%282 585
PFIZER INC.-1.59%203 048
NOVARTIS AG-11.88%202 620
MERCK & CO., INC.-11.97%202 555